Report |

Untangling the Web of Antiretroviral Price Reductions 16th Edition

Photo by Andre Francois

With nearly 13 million people on antiretroviral therapy world-wide, which is less than half the number of people eligible to receive it, the price of antiretroviral (ARV) drugs to put people on treatment remains a critical one.

The 16th edition of Untangling the Web finds that although the price of first- and second-line ARVs have come down thanks to increased generic competition, third-line or salvage regimens remain exorbitantly priced, with middle-income countries such as Armenia paying more than US$13,000 per person per year for raltegravir, just one of the three or four drugs needed in a third-line cocktail.

Patents remain a barrier on newer drugs and in middle-income countries, and will need to be overcome to ensure future access to them.

Additional publications in the Untangling the Web report series are available here.

Learn more about MSF’s work to improve access to lifesaving HIV treatment.

Untangling the Web of Antiretroviral Price Reductions: 16th Edition